Label-Free Array Systems Market Share, Trends, And Growth Forecasts, 2026-2031 Report Released Market Projected To Reach USD 874.12 Million By 2031
Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Label-free Array Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The global label-free array systems market is expected to increase from USD 568.06 million in 2025 to USD 610.33 million in 2026. By 2031, the market is forecast to reach USD 874.12 million, reflecting a 7.44% CAGR during 2026-2031. Growth is being supported by rising pharmaceutical and biotechnology research spending, advances in analytical technologies, and greater demand for high-throughput screening in drug discovery and biomolecular research.
Advantages of Label-free Detection Technologies
Label-free array systems are gaining adoption because they eliminate fluorescent or radioactive tags that can create steric hindrance, signal quenching, and distorted binding kinetics. Their ability to analyze unmodified molecules improves the reliability of interaction data and supports faster screening workflows. Fragment-based research campaigns using these platforms have produced primary hit rates of 12.4%, with 92% crystallographic confirmation.
Eliminating secondary reagents can also reduce assay development time by 40-60%, enabling medicinal-chemistry teams to evaluate candidates and refine research programs more efficiently. Stanford University's SENSBIT platform demonstrated additional durability benefits by retaining 70% of its signal after one month in serum, compared with an 11-hour lifespan for conventional sensors. These performance advantages are accelerating the transition from labeled assays to label-free array technologies.
Pharmaceutical and Biotechnology R&D Investment Drives Demand
Global pharmaceutical R&D spending reached USD 288 billion in 2024, representing a 1.5% year-on-year increase. A growing share of this investment is being directed toward advanced analytical systems capable of generating high-content kinetic data. Merck invested USD 17.9 billion in discovery programs while prioritizing label-free screening capacity.
Demand is also increasing as drug development pipelines shift toward multispecific antibodies, gene editors, and cell therapies. These complex therapeutic programs require accurate interaction analysis for candidate selection and regulatory submissions. Daiichi Sankyo's robotics-enabled laboratory in San Diego reflects this trend by integrating automation, AI, and label-free analytics to shorten bench-to-IND timelines. AI-paired label-free platforms have been associated with Phase 1 success rates of 80-90%, compared with 60-70% for traditional screening approaches.
Technology Trends and Segment Performance
Surface Plasmon Resonance accounted for 41.02% of market revenue in 2025, making it the leading technology segment. Its position is supported by sub-nanomolar detection capabilities and multiplex cartridges that can measure as many as 32 interactions simultaneously. Demand is expected to remain strong as pharmaceutical companies replace aging instruments and expand screening capacity.
Localised Surface Plasmon Resonance is forecast to record the fastest growth, with a 9.56% CAGR. Nano-plasmonic metasurfaces provide enhanced sensitivity for small molecules and offer potential for portable diagnostic applications. National Taiwan University's pH-responsive DNA nanoswitches achieved microRNA detection limits of 0.57 pM, supporting progress toward clinic-ready assays.
Additional advances in whispering-gallery-mode microlasers and nano-fabricated sensor chips are improving biomarker detection and narrowing the distinction between conventional SPR and chip-based LSPR platforms. As sensitivity and pricing differences decline, purchasing decisions are expected to focus increasingly on throughput, service availability, automation, and AI-analytics integration. Other important market influences include rapid upgrades in SPR, BLI, and CDS platforms, alongside the need for stronger user training and technical awareness.
High Instrument Costs Remain a Market Restraint
Capital requirements continue to limit adoption among smaller biotechnology companies and academic laboratories. Premium SPR systems typically cost between USD 200,000 and USD 500,000, while advanced BLI systems can exceed USD 300,000 before service contracts are included. Semiconductor labor shortages, restrictions affecting gallium and germanium supplies, and photonics-sector hiring challenges are increasing component costs and extending delivery times. As a result, many organizations are turning to shared-core laboratories, leasing arrangements, and vendor financing.
Regional Market Outlook
North America led the label-free array systems market with a 44.09% revenue share in 2025. Strong biopharmaceutical investment, established validation pathways, and Thermo Fisher's USD 2 billion domestic expansion plan support regional demand. Boston-Cambridge, the San Francisco Bay Area, and the Raleigh-Durham corridor collectively account for more than 40% of North America's installed label-free systems.
Asia-Pacific is projected to be the fastest-growing region, registering an 8.51% CAGR. China's precision-medicine sector exceeded 2.40 trillion yuan in 2023 and is expanding by approximately 12% annually. India's BioE3 policy prioritizes biomanufacturing, while investments in Japan and new production capacity in Karnataka are strengthening the regional life sciences ecosystem. Subsidized research facilities in Shanghai's Zhangjiang and Hyderabad's Genome Valley are also improving access for start-ups.
Europe maintains a significant market presence through established pharmaceutical hubs in Germany, the United Kingdom, and Switzerland. Manufacturing investments, Horizon Europe grants, and European Innovation Council funding continue to support label-free microfluidics, decentralized testing, and university-industry research partnerships.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Advantages Over Labeled Detection Techniques
4.2.2 Increase In R&D Spending by Pharma & Biotech Firms
4.2.3 Rapid Technology Upgrades In SPR, BLI & CDS Platforms
4.2.4 Integration Of AI Analytics with High-Throughput Label-Free Screens
4.2.5 Adoption In Personalised-Medicine & Cell-Therapy Manufacturing
4.2.6 Nano-Plasmonic & Metasurface Miniaturisation for POC Diagnostics
4.3 Market Restraints
4.3.1 High Capital Cost of Instrumentation
4.3.2 Limited User-Side Awareness & Training
4.3.3 Data-Integration & Standardisation Hurdles for Phenotypic Assays
4.3.4 Shortage Of Nano-Optics Fabrication Talent
4.4 Regulatory Landscape
4.5 Porter's Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Technology
5.1.1 Surface Plasmon Resonance (SPR)
5.1.2 Localised Surface Plasmon Resonance (LSPR)
5.1.3 Bio-Layer Interferometry (BLI)
5.1.4 Cellular Dielectric Spectroscopy (CDS)
5.1.5 Other Technologies
5.2 By Application
5.2.1 Drug Discovery
5.2.2 Protein-Protein / Interface Analysis
5.2.3 Antibody Characterisation & Development
5.2.4 Protein Complex & Cascade Analysis
5.2.5 Other Applications
5.3 By End User
5.3.1 Pharmaceutical & Biotechnology Companies
5.3.2 Contract Research Organisations (CROs)
5.3.3 Academic & R&D Laboratories
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 Danaher Corporation (ForteBio / Molecular Devices)
6.3.2 Bruker Corporation
6.3.3 Corning Incorporated
6.3.4 Thermo Fisher Scientific, Inc.
6.3.5 Sartorius AG (Octet BLI)
6.3.6 Carterra Inc.
6.3.7 GE HealthCare
6.3.8 PerkinElmer, Inc.
6.3.9 Waters Corporation
6.3.10 Agilent Technologies
6.3.11 Nicoya Lifesciences
6.3.12 Gator Bio
6.3.13 Malvern Panalytical
6.3.14 Horiba Ltd.
6.3.15 Attana AB
6.3.16 Quanterix Corp.
6.3.17 Plexera Bioscience
6.3.18 Fluidic Analytics
6.3.19 Delta Life Science
6.3.20 Biosensor Tools LLC
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment